ENHANCE: following children with CF in modern care
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study follows children with cystic fibrosis (CF) and healthy infants over time to understand how CF changes in the modern era of care. It collects health information and tests to learn more about the disease and help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has cystic fibrosis (CF) or is a healthy infant without CF.
- For children with CF: they must be diagnosed through newborn screening, have two CF-causing gene mutations, or be 0–6 years old with a sweat chloride level over 60.
- Healthy infants (without CF) can join as a control group.
- You and your child must be willing to follow all study procedures and attend visits.
- Your child should not have other serious health conditions that could affect the study results (like inflammatory bowel disease or extreme prematurity).
- Children in the control group cannot be carriers of CF gene mutations or have chronic medical or digestive/liver conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls newly diagnosed infants with cystic fibrosis to follow them during “precision medicine” care. It may help doctors better understand which treatments and monitoring work best, especially before certain infections develop.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how cystic fibrosis care is organized when patients take highly effective CFTR modulator drugs. It aims to understand if care needs change for those on modulators compared to those who cannot take them.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.